Summary & Overview
CPT 45381: Colonoscopy with Directed Submucosal Injection
CPT code 45381 is a specialized colonoscopy procedure involving directed submucosal injection, widely used in gastroenterology for both diagnostic and therapeutic purposes. This code is significant nationally due to its role in colorectal disease management, including marking lesions and delivering medications during endoscopic examinations. The procedure is most often performed in outpatient hospital settings, reflecting current clinical practice standards.
Major payers covering this service include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad access for patients across the United States. The publication provides a comprehensive overview of payer coverage, clinical indications, and relevant policy updates. Readers will gain insights into typical use cases, associated diagnoses, and related procedural codes, as well as current billing practices and modifier applications. The analysis also highlights benchmarks and trends in reimbursement, offering a clear understanding of how this procedure fits within the broader landscape of gastroenterology services.
This summary serves as a resource for healthcare professionals, administrators, and policy analysts seeking to understand the clinical and billing context of CPT code 45381, including payer coverage and procedural details.
CPT Code Overview
CPT code 45381 describes a colonoscopy procedure using a flexible scope, during which a directed submucosal injection of any substance is performed. This service is commonly provided within the field of gastroenterology and is typically conducted in an outpatient hospital setting (Place of Service 22). The procedure allows for targeted injection beneath the mucosal layer of the colon, which can be used for a variety of clinical purposes, such as marking lesions or delivering therapeutic agents.
Clinical & Coding Specifications
Clinical Context
A patient presents to the outpatient hospital setting for a colonoscopy due to a history of colon polyps or abnormal findings on prior screening. During the procedure, the gastroenterologist identifies a lesion or area requiring treatment and performs a directed submucosal injection (such as saline, epinephrine, or another substance) to aid in polyp removal, control bleeding, or mark a site for future intervention. The workflow involves pre-procedure assessment, colonoscopy with submucosal injection, and post-procedure monitoring. This service is typically performed by a gastroenterology physician, but may also be provided by family medicine or internal medicine physicians with appropriate training.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component of the procedure (physician's interpretation and report). - Modifier
51: Indicates multiple procedures were performed during the same session. - Modifier
59: Used to denote a distinct procedural service, separate from other procedures performed on the same day. - Modifier
PT: Applied when a colorectal cancer screening test is converted to a diagnostic test or other procedure during the same encounter.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207RG0100X | Gastroenterology Physician |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
Related Diagnoses
-
K63.5: Polyp of colon- Indicates the presence of a colon polyp, which may require submucosal injection during colonoscopy for removal or marking.
-
D12.6: Benign neoplasm of colon, unspecified- Represents a benign tumor in the colon, potentially treated with submucosal injection during colonoscopy.
-
K52.9: Noninfective gastroenteritis and colitis, unspecified- Used when colonoscopy is performed to evaluate or treat noninfective inflammation of the colon, where injection may be indicated.
-
R19.5: Other fecal abnormalities- Applied when abnormal fecal findings prompt colonoscopy and possible submucosal injection.
-
Z12.11: Encounter for screening for malignant neoplasm of colon- Used for screening colonoscopy, which may convert to a diagnostic or therapeutic procedure requiring submucosal injection if abnormalities are found.
Related CPT Codes
-
45380: Colonoscopy, flexible; with biopsy, single or multiple- Used when a biopsy is performed during colonoscopy. May be performed in conjunction with
45381if both biopsy and submucosal injection are needed.
- Used when a biopsy is performed during colonoscopy. May be performed in conjunction with
-
45385: Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique- Used for polyp or lesion removal by snare. May be an alternative or performed together with
45381if injection is used to facilitate removal.
- Used for polyp or lesion removal by snare. May be an alternative or performed together with
-
45378: Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)- Used for diagnostic colonoscopy without therapeutic intervention. May precede or be replaced by
45381if injection is required.
- Used for diagnostic colonoscopy without therapeutic intervention. May precede or be replaced by
-
45382: Colonoscopy, flexible; with control of bleeding, any method- Used when colonoscopy is performed to control bleeding. May be performed with or instead of
45381if injection is used for hemostasis.
- Used when colonoscopy is performed to control bleeding. May be performed with or instead of
National Reimbursement Benchmarks
For CPT code 45381, the national mean rate for Medicare is $508.84, while the BUCA (average commercial) mean rate is $439.46. This indicates that Medicare's average reimbursement is higher than the commercial average for this procedure. Among individual commercial payers, UnitedHealth Group has the highest mean rate at $628.45, and Aetna has the lowest at $308.25.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Aetna shows the tightest range at $148.00, suggesting less variability in rates, while UnitedHealth Group exhibits the widest range at $328.33, indicating greater variability in reimbursement. Cigna and Blue Cross Blue Shield also display substantial dispersion, with ranges of $269.39 and $212.70, respectively.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.